

# **Late-Stage Chronic Kidney Disease Market - A Global and Regional Analysis: Focus on Indication, Treatment Modality, Distribution Channel, Country, and Region - Analysis and Forecast: 2026-2036**

<https://marketpublishers.com/r/LA4E06012FD2EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: LA4E06012FD2EN

## **Abstracts**

The late-stage chronic kidney disease (CKD) market is witnessing robust growth due to the increasing global prevalence of risk factors such as diabetes, hypertension, and an aging population. Late-stage CKD, which often progresses to end-stage renal disease (ESRD), typically requires advanced treatments such as dialysis or kidney transplants.

The market growth is fueled by innovations in dialysis technologies, including portable and home-based systems that enhance patient convenience and treatment adherence. Additionally, the integration of telemedicine and digital health solutions has improved patient management and monitoring, offering new opportunities for disease management. Emerging therapies in regenerative medicine, such as stem cell-based treatments, are also being explored to restore kidney function, potentially reducing the need for dialysis in the future.

The market is particularly buoyed by opportunities in emerging regions such as Asia-Pacific, Latin America, and the Middle East, where the incidence of late-stage CKD is rising alongside improvements in healthcare infrastructure. As awareness of the disease grows, the demand for late-stage CKD treatments is expected to increase in these regions. Furthermore, the development of home dialysis solutions provides patients with greater flexibility, creating new avenues for growth. However, the market faces several challenges, including the high costs associated with dialysis and kidney transplantation, which can be financially burdensome for both patients and healthcare systems. Access to care is another significant issue, particularly in rural and underserved areas where healthcare infrastructure is limited. Additionally, regulatory hurdles and the complexity of

ensuring patient compliance with treatment regimens present ongoing challenges in improving treatment outcomes.

Geographically, North America remains the largest market for late-stage CKD treatments, with the U.S. leading due to its high disease prevalence and advanced healthcare systems. Europe also contributes to market growth, with key players focusing on innovative treatments for late-stage CKD complications. Meanwhile, the Asia-Pacific region is set to experience rapid market expansion due to the rising prevalence of late-stage CKD in countries like China and India, driven by increasing urbanization and lifestyle changes. The competitive landscape is marked by the presence of both established pharmaceutical giants and emerging biotech firms, with companies like Amgen, Fresenius Medical Care, DaVita, and AbbVie dominating the market. These companies are investing in research and development, strategic partnerships, and the expansion of their product portfolios to maintain their market positions. Overall, the late-stage CKD market is poised for growth, with technological advancements, drug development, and emerging regional opportunities paving the way for future progress.

### **Market Segmentation:**

#### Segmentation 1: by Indication

Late-Stage Chronic Kidney Disease Induced Hyperphosphatemia

Late-Stage Chronic Kidney Disease Induced Hyperparathyroidism

Late-Stage Chronic Kidney Disease Induced Hyperkalemia

#### Segmentation 2: by Treatment Modality

Pharmacological Treatment

Dialysis and Renal Replacement Therapies

Surgical Intervention

Therapeutic Devices

## Palliative and Supportive Care

### Segmentation 3: by Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

### Segmentation 4: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days.

## Contents

Executive Summary

Scope of the Study

### **1. GLOBAL LATE-STAGE CHRONIC KIDNEY DISEASE MARKET: INDUSTRY OUTLOOK**

1.1 Market Overview and Ecosystem

1.2 Late-Stage Chronic Kidney Disease Profile

1.3 Epidemiological Analysis of Late-Stage Chronic Kidney Disease Market

1.3.1 Prevalence and Incidence of Bleeding Disorders

1.3.2 Geographic Distribution

1.3.3 Age and Gender Distribution

1.3.4 Impact on Healthcare System

1.4 Market Trends

1.5 Growth Share Analysis by Company

1.6 Regulatory Landscape Analysis

1.6.1 Legal Requirement and Framework in U.S.

1.6.2 Legal Requirement and Framework in E.U.

1.6.3 Legal Requirement and Framework in Asia-Pacific

1.6.4 Legal Requirement and Framework in Rest-of-the-World

1.7 Market Dynamics

1.7.1 Impact Analysis

1.7.2 Market Drivers

1.7.3 Market Restraints

1.7.4 Market Opportunities

### **2. GLOBAL LATE-STAGE CHRONIC KIDNEY DISEASE MARKET, (BY INDICATION), \$MILLION, 2025-2036**

2.1 Overview

2.2 Late-Stage Chronic Kidney Disease Induced Hyperphosphatemia

2.3 Late-Stage Chronic Kidney Disease Induced Hyperparathyroidism

2.4 Late-Stage Chronic Kidney Disease Induced Hyperkalemia

### **3. GLOBAL LATE-STAGE CHRONIC KIDNEY DISEASE MARKET, (BY TREATMENT MODALITY), \$MILLION, 2025-2036**

- 3.1 Overview
- 3.2 Pharmacological Treatment
- 3.3 Dialysis and Renal Replacement Therapies
- 3.4 Surgical Intervention
- 3.5 Therapeutic Devices
- 3.6 Palliative and Supportive Care

#### **4. GLOBAL LATE-STAGE CHRONIC KIDNEY DISEASE MARKET, (BY DISTRIBUTION CHANNEL), \$MILLION, 2025-2036**

- 4.1 Overview
- 4.2 Hospital Pharmacies
- 4.3 Retail Pharmacies
- 4.4 Online Pharmacies

#### **5. GLOBAL LATE-STAGE CHRONIC KIDNEY DISEASE MARKET, (BY REGION), \$MILLION, 2025-2036**

- 5.1 North America
  - 5.1.1 Key Findings
  - 5.1.2 Market Dynamics
  - 5.1.3 Market Sizing and Forecast
    - 5.1.3.1 North America Late-Stage Chronic Kidney Disease Market (by Country)
      - 5.1.3.1.1 U.S.
      - 5.1.3.1.2 Canada
- 5.2 Europe
  - 5.2.1 Key Findings
  - 5.2.2 Market Dynamics
  - 5.2.3 Market Sizing and Forecast
    - 5.2.3.1 Europe Late-Stage Chronic Kidney Disease Market (by Country)
      - 5.2.3.1.1 Germany
      - 5.2.3.1.2 France
      - 5.2.3.1.3 Italy
      - 5.2.3.1.4 Spain
      - 5.2.3.1.5 U.K.
      - 5.2.3.1.6 Rest-of-Europe
- 5.3 Asia-Pacific
  - 5.3.1 Key Findings
  - 5.3.2 Market Dynamics

### 5.3.3 Market Sizing and Forecast

#### 5.3.3.1 Asia-Pacific Late-Stage Chronic Kidney Disease Market (by Country)

##### 5.3.3.1.1 Japan

##### 5.3.3.1.2 China

##### 5.3.3.1.3 Rest-of-Asia-Pacific

### 5.4 Rest-of-the-World

#### 5.4.1 Key Findings

#### 5.4.2 Market Dynamics

#### 5.4.3 Market Sizing and Forecast

## 6. COMPETITIVE BENCHMARKING AND COMPANY PROFILES

### 6.1 Competitive Benchmarking

### 6.2 Competitive Landscape

#### 6.2.1 Key Strategies and Developments by Company

##### 6.2.1.1 Funding Activities

##### 6.2.1.2 Mergers and Acquisitions

##### 6.2.1.3 Regulatory Approvals

##### 6.2.1.4 Partnerships, Collaborations, and Business Expansions

#### 6.2.2 Key Developments Analysis

### 6.3 Company Profiles

#### 6.3.1 Novartis AG

##### 6.3.1.1 Company Overview

##### 6.3.1.2 Product Portfolio

##### 6.3.1.3 Target Customers/End Users

##### 6.3.1.4 Key Personnel

##### 6.3.1.5 Analyst View

#### 6.3.2 Merck & Co., Inc.

##### 6.3.2.1 Company Overview

##### 6.3.2.2 Product Portfolio

##### 6.3.2.3 Target Customers/End Users

##### 6.3.2.4 Key Personnel

##### 6.3.2.5 Analyst View

#### 6.3.3 Pfizer, Inc.

##### 6.3.3.1 Company Overview

##### 6.3.3.2 Product Portfolio

##### 6.3.3.3 Target Customers/End Users

##### 6.3.3.4 Key Personnel

##### 6.3.3.5 Analyst View

#### 6.3.4 Sanofi

6.3.4.1 Company Overview

6.3.4.2 Product Portfolio

6.3.4.3 Target Customers/End Users

6.3.4.4 Key Personnel

6.3.4.5 Analyst View

#### 6.3.5 Johnson & Johnson

6.3.5.1 Company Overview

6.3.5.2 Product Portfolio

6.3.5.3 Target Customers/End Users

6.3.5.4 Key Personnel

6.3.5.5 Analyst View

## 7. RESEARCH METHODOLOGY

## List Of Figures

### LIST OF FIGURES

Figure: Late-Stage Chronic Kidney Disease Market (by Scenario), \$Million, 2025, 2030, and 2036

Figure: Global Late-Stage Chronic Kidney Disease Market, 2025 and 2036

Figure: Global Late-Stage Chronic Kidney Disease Market Key Trends, Impact Analysis

Figure: North America Late-Stage Chronic Kidney Disease Market, \$Million, 2025-2036

Figure: Europe Late-Stage Chronic Kidney Disease Market, \$Million, 2025-2036

Figure: Asia-Pacific Late-Stage Chronic Kidney Disease Market, \$Million, 2025-2036

Figure: Rest-of-the-World Late-Stage Chronic Kidney Disease Market, \$Million, 2025-2036

## List Of Tables

### LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Late-Stage Chronic Kidney Disease Market (by Indication), \$Million, 2025-2036

Table: Global Late-Stage Chronic Kidney Disease Market (by Treatment Modality), \$Million, 2025-2036

Table: Global Late-Stage Chronic Kidney Disease Market (by Distribution Channel), \$Million, 2025-2036

Table: Global Late-Stage Chronic Kidney Disease Market (by Region), \$Million, 2025-2036

## I would like to order

Product name: Late-Stage Chronic Kidney Disease Market - A Global and Regional Analysis: Focus on Indication, Treatment Modality, Distribution Channel, Country, and Region - Analysis and Forecast: 2026-2036

Product link: <https://marketpublishers.com/r/LA4E06012FD2EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LA4E06012FD2EN.html>